SRPT
Sarepta Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.73
+3.68%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$17.25
From 52W high−27.48%
Volume2.19M
Market cap$1.87B
P/E (TTM)—
P/S (TTM)0.9x
Div yield—
Key dataOct 19, 2026
Open
$17.25
From 52W high
−27.48%
Volume
2.19M
Market cap
$1.87B
ValuationView details →
P/E (Fwd)
49.1x
EV/EBITDA
−146.1x
P/E (TTM)
—
RSI (14)
45.7
MomentumView details →
1D Return
+3.68%
YTD Return
−18.08%
SummaryUpdated Jun 1, 2026
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company founded in 1980 and headquartered in Cambridge, Massachusetts. The company went public in 1997 and has evolved from a research-focused organization into a leading developer of RNA-targeted therapeutics and gene therapies for rare neuromuscular diseases. Sarepta achieved a major milestone in 2023 with the FDA approval of ELEVIDYS, the first gene therapy for Duchenne muscular dystrophy, transforming the company from a loss-making biotech into a profitable enterprise with over $1.9 billion in annual revenue as of 2024.
Similar companies
Latest newsMore news →
Sarepta Therapeutics presented new data at the 31st Annual Congress of the World Muscle Society showing clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory patients with Duchenne muscular dystrophy.20d agoSarepta Therapeutics announced it will present new data from its Duchenne muscular dystrophy treatment portfolio, including a late-breaking poster on delandistrogene moxeparvovec, at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan, on Sept. 29 - Oct. 3.25d agoSarepta Therapeutics announced it will present new data from its neuromuscular portfolio, including first results from the Phase 4 ENDURE Study, at the 27th Annual Neuromuscular Study Group Scientific Meeting on Sept. 25-27, 2026, in San Antonio, Texas.26d ago